PMID- 36715956
OWN - NLM
STAT- MEDLINE
DCOM- 20230703
LR  - 20230703
IS  - 1573-2630 (Electronic)
IS  - 0165-5701 (Linking)
VI  - 43
IP  - 7
DP  - 2023 Jul
TI  - Implantable sustained-release drug delivery systems: a revolution for ocular 
      therapeutics.
PG  - 2575-2588
LID - 10.1007/s10792-023-02637-x [doi]
AB  - PURPOSE: Due to the inimitable anatomical structure of the eyeball and various 
      physiological barriers, conventional ocular local administration is often 
      complicated by apparent shortcomings, such as limited bioavailability and short 
      drug retention. Thus, developing methods for sustainable, safe and efficient drug 
      delivery to ocular target sites has long been an urgent need. This study briefly 
      summarizes the barriers to ocular drug administration and various ocular drug 
      delivery routes and highlights recent progress in ocular implantable 
      sustained-release drug delivery systems (DDSs) to provide literature evidence for 
      developing novel ocular implants for sustained drug delivery. METHODS: We 
      conducted a comprehensive search of studies on ocular implantable 
      sustained-release DDSs in PubMed and Web of Science using the following keywords: 
      ocular, implantable and drug delivery system. More than 400 papers were 
      extracted. Publications focused on sustained and controlled drug release were 
      primarily considered. Experimental articles involving DDSs that cannot be 
      implanted into the eye through surgeries and cannot be inserted into ocular 
      tissues in solid form were excluded. Approximately 143 publications were reviewed 
      to summarize the most current information on the subject. RESULTS: In recent 
      years, numerous ocular sustained-release DDSs using lipids, nanoparticles and 
      hydrogels as carriers have emerged. With unique properties and systematic design, 
      ocular implantable sustained-release DDSs are able to continuously maintain drug 
      release, effectively sustain the therapeutic concentration in target tissues, and 
      substantially enhance the therapeutic efficacy. Nevertheless, few ocular 
      implantable sustained-release DDSs have been available in clinical use. 
      CONCLUSIONS: Ocular implantable sustained-release DDSs have become a new focus in 
      the field of ocular drug development through unique designs and improvements in 
      the materials of drug carriers, administration methods and dosage forms. With 
      more ocular implantable sustained-release DDSs being commercialized, ocular 
      therapeutics may be revolutionized.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature B.V.
FAU - Cong, Yun-Yi
AU  - Cong YY
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, 
      130000, China.
FAU - Fan, Bin
AU  - Fan B
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, 
      130000, China.
FAU - Zhang, Zi-Yuan
AU  - Zhang ZY
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, 
      130000, China.
FAU - Li, Guang-Yu
AU  - Li GY
AD  - Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, 
      130000, China. liguangyu@aliyun.com.
LA  - eng
GR  - 82171053/the National Natural Science Foundation of China/
GR  - 20200801043GH/he Natural Science Foundation of Jilin Province/
GR  - 20190201083JC/the Natural Science Foundation of Jilin Province/
PT  - Journal Article
PT  - Review
DEP - 20230130
PL  - Netherlands
TA  - Int Ophthalmol
JT  - International ophthalmology
JID - 7904294
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Humans
MH  - Delayed-Action Preparations/pharmacology/therapeutic use
MH  - *Eye
MH  - *Drug Delivery Systems
MH  - Drug Carriers/chemistry/pharmacology
MH  - Administration, Ophthalmic
OTO - NOTNLM
OT  - Drug delivery system
OT  - Implant
OT  - Ocular barrier
OT  - Sustained-release
EDAT- 2023/01/31 06:00
MHDA- 2023/07/03 06:41
CRDT- 2023/01/30 11:27
PHST- 2022/09/13 00:00 [received]
PHST- 2023/01/10 00:00 [accepted]
PHST- 2023/07/03 06:41 [medline]
PHST- 2023/01/31 06:00 [pubmed]
PHST- 2023/01/30 11:27 [entrez]
AID - 10.1007/s10792-023-02637-x [pii]
AID - 10.1007/s10792-023-02637-x [doi]
PST - ppublish
SO  - Int Ophthalmol. 2023 Jul;43(7):2575-2588. doi: 10.1007/s10792-023-02637-x. Epub 
      2023 Jan 30.